BAFF CHO Cell Line

BAFF CHO Cell Line is a clonal CHO cell line stably expressing full-length human BAFF (TNF family ligand B-cell Activating Factor) (NM_006573.5). The expressed BAFF may be released as a soluble form by proteolytic cleavage. This cell line was validated by flow cytometry, and in a co-culture assay with BAFF/APRIL Responsive BCMA-NF-kappaB Luciferase Reporter HEK293 Cell Line (#79755) in the presence of Belimumab. BAFF (TNF family ligand B-cell Activating Factor), also known as BLyS, TALL-1 or CD257, is encoded by the TNFSF13B (Tumor necrosis factor super family member 13B) gene and is a Type II membrane-bound protein, which can be released as a soluble ligand upon proteolytic processing. This cytokine is a ligand for the receptors Transmembrane Activator and CAML Interactor (TACI or TNFRSF13B), BAFF Receptor (BAFFR, or TNFRSF13C), and B-cell Maturation Antigen (BCMA, TNFRSF17). These interactions promote cell survival and play a crucial role in B cell development. In particular, BAFFR signaling is important in the later stages of B cell differentiation, including the survival of long-lived bone marrow plasma cells and likely for the survival of plasma blasts. BAFF signaling is also required for CCL (chronic lymphocytic leukemia) cell survival. Binding of BAFF to BAFFR results in the degradation of TRAF3 (TNF receptor associated factor 3), which stops the inhibition of SYK and results in activation of pathways necessary for B cells. It also activates the non-canonical slow NF-kappaB2-dependent pathway, which relies on the activation of NIK (NF-kappaB-inducing kinase). Targeting BAFF-BAFFR will open new therapeutic avenues in diseases related to these proteins.